Partnerships

Janssen Pharmaceuticals collaborates with CureVac and DCPrime in vaccines.

Advanced Biosciences Laboratories will support the development and production of a novel Shigella vaccine candidate for PATH.

J&J's Janssen and PATH partner to improve drug formulation that could help prevent HIV infection.

Are strategic partnerships in clinical research a model for CMC services?

ScinoPharm Changshu Pharmaceuticals and Sundia MediTech form an alliance for contract research and manufacturing services in mainland China.

Oncobiologics, Inc. and inVentiv Health announced a global strategic partnership around clinical development for all assets in Oncobiologic?s biosimilar pipeline.

The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies.

Companies hope the collaboration will result in identifying potential new drug candidates using fewer rounds of design, synthesis, and testing.

The move is part of a strategy to cultivate innovation in key regions.

The multimillion deal focuses on oncology.

Agreement seeks to advance novel drug targets and focus on therapies for ulcerative colitis.

The agreement is worth up to $552 million, depending on meeting set milestones.

-

An innovative approach to capacity management.

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals have announced a follow-on collaboration to advance the development of malaria vaccines and new vaccine delivery technologies.

GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.

Working together affords many unseen opportunities for pharmaceutical innovation.

Pfizer and Mylan have agreed to establish an exclusive long-term collaboration to develop, manufacture, distribute, and market generic drugs in Japan. The products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling.

Gilead Sciences announced that it is entering into agreements with Indian generic drug manufacturers to enhance access in developing countries to its anti-HIV medicine, emtricitabine.

Collaborative R&D models coincide with new ways to fund translational research.

Future sponsor-contract provider relationships will require more integration.

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The US Pharmacopeia (USP) continues to expand its collaboration with drug authorities around the world, this time with Brazil?s regulatory agency. USP and the Brazilian National Agency of Sanitary Surveillance (ANVISA) are teaming up to develop joint education activities for professionals involved in formulating and using pharmacopeial monograph standards in Brazil, according to news releases on the USP website.

Pfizer has partnered with the University of California?s San Diego Health Sciences (UCSD) in a drug-discovery collaboration that could see Pfizer invest up to $50 million over the next five years in the development of new therapies. The partnership will leverage UCSD?s expertise in neurosciences, cancer, inflammation, metabolism, clinical pharmacology, HIV, and pain.

In a speech at Carnegie Mellon University?s National Robotics Engineering Center last Friday, President Obama unveiled an Advanced Manufacturing Partnership (AMP) designed to reinvigorate the country?s manufacturing sector. The partnership between academics, business leaders, and science and technology agencies is intended to create jobs by helping US manufacturers reduce costs, improve quality, and accelerate product development.